OA11038A - Pharmaceutical compositions containing lamivudine and zidovudine - Google Patents

Pharmaceutical compositions containing lamivudine and zidovudine Download PDF

Info

Publication number: OA11038A
Authority: OA; OAPI
Prior art keywords: zidovudine; amount; pharmaceutical composition; lamivudine; glidant
Prior art date: 1996-10-31

Application number

OA9900088A

Other languages

English (en)

Inventor

Katherine Jeannette Ford

Gary Wayne Goodson

Allen Wayne Wood

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-31

Filing date

1999-04-23

Publication date

2002-02-06

1999-04-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2002-02-06 Publication of OA11038A publication Critical patent/OA11038A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 title description 8
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract description 37
229960001627 lamivudine Drugs 0.000 claims abstract description 37
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 36
229960002555 zidovudine Drugs 0.000 claims abstract description 34
238000000034 method Methods 0.000 claims abstract description 17
230000002401 inhibitory effect Effects 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 41
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 39
239000000377 silicon dioxide Substances 0.000 claims description 17
235000012239 silicon dioxide Nutrition 0.000 claims description 17
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 16
239000002552 dosage form Substances 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 9
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
229920002472 Starch Polymers 0.000 claims description 7
239000008107 starch Substances 0.000 claims description 7
235000019698 starch Nutrition 0.000 claims description 7
239000001913 cellulose Substances 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
239000008108 microcrystalline cellulose Substances 0.000 claims description 5
229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
229920002261 Corn starch Polymers 0.000 claims description 4
206010038997 Retroviral infections Diseases 0.000 claims description 4
239000010425 asbestos Substances 0.000 claims description 4
239000011575 calcium Substances 0.000 claims description 4
229910052791 calcium Inorganic materials 0.000 claims description 4
229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
235000010216 calcium carbonate Nutrition 0.000 claims description 4
239000000378 calcium silicate Substances 0.000 claims description 4
229910052918 calcium silicate Inorganic materials 0.000 claims description 4
235000012241 calcium silicate Nutrition 0.000 claims description 4
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 4
239000008120 corn starch Substances 0.000 claims description 4
-1 metallic stéarates Substances 0.000 claims description 4
235000019814 powdered cellulose Nutrition 0.000 claims description 4
229920003124 powdered cellulose Polymers 0.000 claims description 4
229910052895 riebeckite Inorganic materials 0.000 claims description 4
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
239000004299 sodium benzoate Substances 0.000 claims description 4
235000010234 sodium benzoate Nutrition 0.000 claims description 4
239000000454 talc Substances 0.000 claims description 4
229910052623 talc Inorganic materials 0.000 claims description 4
235000012222 talc Nutrition 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
229910000503 Na-aluminosilicate Inorganic materials 0.000 claims description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 3
229940043264 dodecyl sulfate Drugs 0.000 claims description 3
239000005022 packaging material Substances 0.000 claims description 3
239000000429 sodium aluminium silicate Substances 0.000 claims description 3
235000012217 sodium aluminium silicate Nutrition 0.000 claims description 3
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
239000011701 zinc Substances 0.000 claims description 3
229910052725 zinc Inorganic materials 0.000 claims description 3
238000004806 packaging method and process Methods 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
229910000323 aluminium silicate Inorganic materials 0.000 claims 1
239000011248 coating agent Substances 0.000 claims 1
238000000576 coating method Methods 0.000 claims 1
HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
239000000463 material Substances 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
241001430294 unidentified retrovirus Species 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 26
230000000840 anti-viral effect Effects 0.000 abstract description 4
239000003414 pharmaceutical glidant Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 description 19
239000003814 drug Substances 0.000 description 17
229940079593 drug Drugs 0.000 description 16
238000011282 treatment Methods 0.000 description 14
241000124008 Mammalia Species 0.000 description 9
238000007906 compression Methods 0.000 description 8
230000006835 compression Effects 0.000 description 8
238000009472 formulation Methods 0.000 description 8
239000000843 powder Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
238000011269 treatment regimen Methods 0.000 description 5
241000700605 Viruses Species 0.000 description 3
239000007894 caplet Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000002718 pyrimidine nucleoside Substances 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
YFUCIEVRSCGPFH-UHFFFAOYSA-N 1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1SC(CO)OC1N1C(=O)N=CC=C1 YFUCIEVRSCGPFH-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
241000792859 Enema Species 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000031689 negative regulation of reverse transcription Effects 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004886 process control Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
239000010959 steel Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940120938 zidovudine and lamivudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Immunology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

OA9900088A 1996-10-31 1999-04-23 Pharmaceutical compositions containing lamivudine and zidovudine OA11038A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9622681.6A GB9622681D0 (en)	1996-10-31	1996-10-31	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
OA11038A true OA11038A (en)	2002-02-06

Family

ID=10802224

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900088A OA11038A (en)	1996-10-31	1999-04-23	Pharmaceutical compositions containing lamivudine and zidovudine

Country Status (43)

Country	Link
EP (1)	EP0941100B1 (fr)
JP (1)	JP2001502718A (fr)
KR (1)	KR100551652B1 (fr)
AP (1)	AP1067A (fr)
AR (1)	AR009135A1 (fr)
AT (1)	ATE241364T1 (fr)
AU (1)	AU736607B2 (fr)
BG (1)	BG64541B1 (fr)
BR (1)	BR9712614A (fr)
CA (1)	CA2270174A1 (fr)
CO (1)	CO4930269A1 (fr)
CY (1)	CY2485B1 (fr)
CZ (1)	CZ296080B6 (fr)
DE (1)	DE69722433T2 (fr)
DK (1)	DK0941100T3 (fr)
EA (1)	EA002437B1 (fr)
EE (1)	EE03806B1 (fr)
ES (1)	ES2200204T3 (fr)
GB (1)	GB9622681D0 (fr)
GE (1)	GEP20022735B (fr)
GT (1)	GT199700116A (fr)
HR (1)	HRP970569B1 (fr)
HU (1)	HU224969B1 (fr)
ID (1)	ID18698A (fr)
IL (1)	IL129422A0 (fr)
IS (1)	IS5024A (fr)
MY (1)	MY119513A (fr)
NO (1)	NO317163B1 (fr)
NZ (1)	NZ335153A (fr)
OA (1)	OA11038A (fr)
PA (1)	PA8441101A1 (fr)
PE (1)	PE10099A1 (fr)
PL (1)	PL190349B1 (fr)
PT (1)	PT941100E (fr)
SI (1)	SI0941100T1 (fr)
SK (1)	SK284286B6 (fr)
SV (1)	SV1997000090A (fr)
TR (1)	TR199900950T2 (fr)
UA (1)	UA64725C2 (fr)
UY (1)	UY24766A1 (fr)
WO (1)	WO1998018477A2 (fr)
YU (1)	YU19999A (fr)
ZA (1)	ZA979726B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9622681D0 (en) *	1996-10-31	1997-01-08	Glaxo Group Ltd	Pharmaceutical compositions
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
US7074417B2 (en) *	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
US20050175694A1 (en) *	2002-04-23	2005-08-11	Himadri Sen	Long acting compositions comprising zidovudine and lamivudine
ATE361059T1 (de) *	2002-11-08	2007-05-15	Glaxo Group Ltd	Antivirale zusammensetzungen
JP4996241B2 (ja)	2003-01-14	2012-08-08	ギリアードサイエンシーズ，インコーポレイテッド	組み合わせ抗ウイルス治療のための組成物および方法
AR045841A1 (es) *	2004-09-28	2005-11-16	Richmond Sa Com Ind Y Financie	Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r, 8r, 10r,11r)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CA2866133A1 (fr)	2012-03-05	2013-09-12	Cipla Limited	Combinaisons pharmaceutiques antiretrovirales comprenant de la lamivudine, du festinavir et de la nevirapine
US20140234415A1 (en) *	2013-02-20	2014-08-21	Abbvie Inc.	Tablet Dosage Forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4950652A (en) *	1987-03-23	1990-08-21	Hem Research, Inc.	dsRNAs for combination therapy in the treatment of viral diseases
GB9110624D0 (en) *	1991-05-16	1991-07-03	Glaxo Group Ltd	Combinations
DE69206876T3 (de) *	1991-05-16	2004-08-12	Glaxo Group Ltd., Greenford	Nukleosidanalogen enthaltende Antiviren-Zubereitungen
GB9622681D0 (en) *	1996-10-31	1997-01-08	Glaxo Group Ltd	Pharmaceutical compositions

1996
- 1996-10-31 GB GBGB9622681.6A patent/GB9622681D0/en active Pending
1997
- 1997-10-24 HR HR970569A patent/HRP970569B1/xx not_active IP Right Cessation
- 1997-10-28 CO CO97063174A patent/CO4930269A1/es unknown
- 1997-10-28 SV SV1997000090A patent/SV1997000090A/es not_active Application Discontinuation
- 1997-10-28 MY MYPI97005103A patent/MY119513A/en unknown
- 1997-10-29 AR ARP970105027A patent/AR009135A1/es unknown
- 1997-10-29 EP EP97950036A patent/EP0941100B1/fr not_active Expired - Lifetime
- 1997-10-29 GT GT199700116A patent/GT199700116A/es unknown
- 1997-10-29 DE DE69722433T patent/DE69722433T2/de not_active Expired - Lifetime
- 1997-10-29 CZ CZ0155799A patent/CZ296080B6/cs not_active IP Right Cessation
- 1997-10-29 JP JP10520045A patent/JP2001502718A/ja active Pending
- 1997-10-29 DK DK97950036T patent/DK0941100T3/da active
- 1997-10-29 TR TR1999/00950T patent/TR199900950T2/xx unknown
- 1997-10-29 SI SI9730570T patent/SI0941100T1/xx unknown
- 1997-10-29 PE PE1997000965A patent/PE10099A1/es not_active Application Discontinuation
- 1997-10-29 YU YU19999A patent/YU19999A/sh unknown
- 1997-10-29 HU HU0000344A patent/HU224969B1/hu not_active IP Right Cessation
- 1997-10-29 IL IL12942297A patent/IL129422A0/xx not_active IP Right Cessation
- 1997-10-29 SK SK575-99A patent/SK284286B6/sk unknown
- 1997-10-29 KR KR1019997003757A patent/KR100551652B1/ko not_active Expired - Fee Related
- 1997-10-29 GE GEAP19974781A patent/GEP20022735B/en unknown
- 1997-10-29 EA EA199900345A patent/EA002437B1/ru not_active IP Right Cessation
- 1997-10-29 ES ES97950036T patent/ES2200204T3/es not_active Expired - Lifetime
- 1997-10-29 PL PL97333143A patent/PL190349B1/pl unknown
- 1997-10-29 AT AT97950036T patent/ATE241364T1/de active
- 1997-10-29 AP APAP/P/1999/001519A patent/AP1067A/en active
- 1997-10-29 EE EEP199900175A patent/EE03806B1/xx not_active IP Right Cessation
- 1997-10-29 BR BR9712614-4A patent/BR9712614A/pt not_active IP Right Cessation
- 1997-10-29 AU AU53142/98A patent/AU736607B2/en not_active Ceased
- 1997-10-29 NZ NZ335153A patent/NZ335153A/en unknown
- 1997-10-29 CA CA002270174A patent/CA2270174A1/fr not_active Abandoned
- 1997-10-29 UA UA99042239A patent/UA64725C2/uk unknown
- 1997-10-29 PT PT97950036T patent/PT941100E/pt unknown
- 1997-10-29 ZA ZA979726A patent/ZA979726B/xx unknown
- 1997-10-29 WO PCT/EP1997/005953 patent/WO1998018477A2/fr not_active Ceased
- 1997-10-30 UY UY24766A patent/UY24766A1/es not_active IP Right Cessation
- 1997-10-30 PA PA19978441101A patent/PA8441101A1/es unknown
- 1997-10-30 ID IDP973554A patent/ID18698A/id unknown
1999
- 1999-04-09 IS IS5024A patent/IS5024A/is unknown
- 1999-04-23 OA OA9900088A patent/OA11038A/en unknown
- 1999-04-29 NO NO19992091A patent/NO317163B1/no unknown
- 1999-05-26 BG BG103435A patent/BG64541B1/bg unknown
2004
- 2004-11-26 CY CY0400085A patent/CY2485B1/xx unknown

Also Published As

Publication number	Publication date
DE69722433T2 (de)	2004-04-08
PE10099A1 (es)	1999-03-02
ATE241364T1 (de)	2003-06-15
IL129422A0 (en)	2000-02-17
NO317163B1 (no)	2004-08-30
CA2270174A1 (fr)	1998-05-07
GB9622681D0 (en)	1997-01-08
SK284286B6 (sk)	2005-01-03
PA8441101A1 (es)	2000-05-24
NO992091D0 (no)	1999-04-29
HK1020880A1 (en)	2000-05-26
HUP0000344A3 (en)	2002-04-29
ID18698A (id)	1998-04-30
AU5314298A (en)	1998-05-22
GT199700116A (es)	1999-04-22
HUP0000344A2 (hu)	2001-05-28
PL190349B1 (pl)	2005-11-30
IS5024A (is)	1999-04-09
WO1998018477A3 (fr)	1998-06-18
BR9712614A (pt)	1999-10-26
BG103435A (en)	2000-04-28
NZ335153A (en)	2001-04-27
UA64725C2 (uk)	2004-03-15
AP9901519A0 (en)	1999-06-30
WO1998018477A2 (fr)	1998-05-07
DK0941100T3 (da)	2003-09-01
UY24766A1 (es)	2000-12-29
HRP970569B1 (en)	2004-10-31
AP1067A (en)	2002-05-01
YU19999A (sh)	2000-10-30
CY2485B1 (en)	2005-06-03
KR20000052893A (ko)	2000-08-25
TR199900950T2 (xx)	1999-07-21
JP2001502718A (ja)	2001-02-27
DE69722433D1 (de)	2003-07-03
HRP970569A2 (en)	1998-08-31
SV1997000090A (es)	1998-10-07
AR009135A1 (es)	2000-03-08
PT941100E (pt)	2003-10-31
BG64541B1 (bg)	2005-07-29
NO992091L (no)	1999-06-29
SI0941100T1 (en)	2003-12-31
EP0941100B1 (fr)	2003-05-28
EP0941100A2 (fr)	1999-09-15
CZ155799A3 (cs)	1999-10-13
EE03806B1 (et)	2002-08-15
EA002437B1 (ru)	2002-04-25
ZA979726B (en)	1999-04-29
MY119513A (en)	2005-06-30
SK57599A3 (en)	2000-06-12
AU736607B2 (en)	2001-08-02
CO4930269A1 (es)	2000-06-27
GEP20022735B (en)	2002-07-25
EE9900175A (et)	1999-12-15
ES2200204T3 (es)	2004-03-01
EA199900345A1 (ru)	2000-02-28
PL333143A1 (en)	1999-11-22
CZ296080B6 (cs)	2006-01-11
KR100551652B1 (ko)	2006-02-13
HU224969B1 (en)	2006-04-28

Publication	Publication Date	Title
US6113920A (en)	2000-09-05	Pharmaceutical compositions
CA2330391A1 (fr)	1999-11-04	Compositions pharmaceutiques homogenes comportant de l'abacavir, de la lamiduvine et de la zidovudine
AP1067A (en)	2002-05-01	Pharmaceutical compositions containing lamivudine and zidovudine.
KR20200070246A (ko)	2020-06-17	이중층 제약 정제 제제
EP1567133B1 (fr)	2007-05-02	Preparations pharmaceutiques antivirales
US20050171127A1 (en)	2005-08-04	Pharmaceutical compositions comprising abacavir and lamivudine
HK1020880B (en)	2003-11-28	Pharmaceutical compositions containing lamivudine and zidovudine
US20030004130A1 (en)	2003-01-02	Homogeneous pharmaceutical compositions containing zidovudine and lamivudine
MXPA99004025A (en)	2000-02-02	Pharmaceutical compositions containing lamivudine and zidovudine
CN1241142A (zh)	2000-01-12	含有拉米夫定和齐多夫定的药用组合物
US20050113394A1 (en)	2005-05-26	Pharmaceutical compositions
GB2082910A (en)	1982-03-17	Anti-depressant compositions
US4005203A (en)	1977-01-25	Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine
US4716177A (en)	1987-12-29	Tolrestat for inhibition of weight gain